Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. August 2018 07:30 ET | Quelle: Orgenesis Inc.

Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold Technology for Cell Transplantation

GERMANTOWN, Md. and BEER-SHEVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a manufacturer, service provider and developer of advanced cell therapies, along with BGN...
15. August 2018 08:30 ET | Quelle: Orgenesis Inc.

Orgenesis Announces that Dr. Ohad Karnieli, CEO of Atvio Biotech, a Wholly-Owned Subsidiary of Masthercell Global, will Present at the 2018 Bioprocessing Summit

GERMANTOWN, Md., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq: ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, today...
30. Juli 2018 08:30 ET | Quelle: Orgenesis Inc.

Orgenesis Announces Collaboration between Secant Group and Atvio Biotech, a Wholly Owned Subsidiary of Masthercell Global, to Develop and Commercialize Scaffold Technologies for Advanced Cell Therapies

Secant Group and Atvio Biotech to advance project under $1.8 million grant from the Israel-U.S. Binational Industrial R&D Foundation Orgenesis to utilize scaffold technology for its autologous...
17. Juli 2018 10:53 ET | Quelle: Orgenesis Inc.

Orgenesis Reports 73% Increase in Revenue for the Second Quarter of Fiscal 2018

GERMANTOWN, Md., July 17, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and...
29. Juni 2018 07:30 ET | Quelle: Orgenesis Inc.

Orgenesis Forms Strategic Partnership with Leading Healthcare Fund and Reports Planned Investment of up to $25 Million into MaSTherCell Subsidiary

Consolidates Global CDMO Business Including Belgian Subsidiary MaSTherCell S.A., Israeli Partner Atvio Biotech and Korean Partner Curecell Co. Announces Plans to Enter U.S. Market and Expand Global...
25. Juni 2018 09:12 ET | Quelle: Orgenesis Inc.

Orgenesis Inc. Added to Russell Microcap® Index

GERMANTOWN, Md., June 25, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced...
04. Juni 2018 12:20 ET | Quelle: Orgenesis Inc.

Orgenesis CDMO Partner Atvio Biotechnology’s CEO to Present on Roundtable at the 2018 BIO International Convention

GERMANTOWN, Md., June 04, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced...
16. Mai 2018 01:19 ET | Quelle: Orgenesis Inc.

Orgenesis and Atvio Biotechnology to Present at the World Advanced Therapies & Regenerative Medicine Congress

GERMANTOWN, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, announced today that the Company, along...
30. April 2018 08:30 ET | Quelle: Orgenesis Inc.

Orgenesis Appoints Professor Lorenzo Piemonti to Scientific Advisory Board

GERMANTOWN, Md., April 30, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced it has appointed...
19. April 2018 10:03 ET | Quelle: Orgenesis Inc.

Orgenesis Reports 42% Increase in Revenue for the First Quarter of Fiscal 2018

GERMANTOWN, Md., April 19, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and...

Vorherige Seite